Search This Blog

Tuesday, July 28, 2020

Coronavirus could cause mass exodus of Wall Street firms in NYC

New York City faces a mass exodus of Wall Street firms — and jobs — as some financial and professional-services industries consider trimming their presence in the city by at least 20 percent because of the coronavirus pandemic, according to a new study.
About one in four office employers intend to reduce their footprint in the city by about 20 percent or more, according to findings published by the Partnership for New York City, a group consisting of top corporate CEOs. Roughly 16 percent plan to relocate jobs from New York City to the suburbs or other locations.
Half of the companies surveyed expect just 75 percent of their workforce to return to the office full-time. What’s more, companies only expect 10 percent of their employees to return to the office this summer and just 40 percent by the end of the year, according to the study, which was conducted in mid-May and published last week.
“Based on these responses, COVID-19 will accelerate the hollowing out of mid-level jobs in the financial sector,” the study found.
The worst economic downturn in nearly a century is bleeding the city of revenue: According to the study, New York could lose more than $37 billion in state and city tax revenue over the next two fiscal years.
The massive losses are already evident in the balance sheet. In May, state tax receipts were down 20 percent, and city sales tax collections were down 32 percent, amounting to $196 million in lost revenues in a single month.

“Depending on how quickly the economy recovers and whether there is a recurrence of disease, these losses could be deeper,” the study said. “Federal reimbursement for state and city losses is anticipated, but deep cuts in expenses, as well as possible tax increases, will likely be needed to bridge what is expected to be a three-year trough in revenues.”
Small businesses have been particularly hard-hit by the pandemic and subsequent economic shutdown, resulting in a big hit to the real-estate sector. Owners of mixed-use apartment buildings have reported that that rent collection plunged 60 percent from commercial tenants.
Nearly all of the city’s tax revenue stems from real estate.

In April, New York City and state collected a combined $78.5 million in tax revenue on the sale of commercial and residential properties — well below March, when it raked in $217.5 million, according to a report published by the Real Estate Board of New York.
That marks a 64 decrease from March, and a 48 percent loss from year over year, according to the report.
“This dramatic loss in tax revenue is alarming,” real estate board President James Whelan said in a statement. “The real estate sector is the city’s economic engine. The pandemic has caused that engine to stall and we should expect such alarming trends to carry through May and June in the best-case scenario.”

Science publishing opened up in pandemic: Will it stay that way?

Scientific publishing is not known for moving rapidly. In normal times, publishing new research can take months, if not years. Researchers prepare a first version of a paper on new findings and submit it to a journal, where it is often rejected, before being resubmitted to another journal, peer-reviewed, revised and, eventually, hopefully published.
All scientists are familiar with the process, but few love it or the time it takes. And even after all this effort—for which neither the authors, the peer reviewers, nor most journal editors, are paid—most research papers end up locked away behind expensive journal paywalls. They can only be read by those with access to funds or to institutions that can afford subscriptions.
What we can learn from SARS
The business-as-usual process is poorly equipped to handle a fast-moving emergency. In the 2003 SARS outbreaks in Hong Kong and Toronto, for example, only 22% of the epidemiological studies on SARS were even submitted to journals during the outbreak. Worse, only 8% were accepted by journals and 7% published before the crisis was over.
Fortunately, SARS was contained in a few months, but perhaps it could have been contained even quicker with better sharing of research.
Fast-forward to the COVID-19 , and the situation could not be more different. A highly infectious virus spreading across the globe has made rapid sharing of research vital. In many ways, the publishing rulebook has been thrown out the window.
Preprints and journals
In this medical emergency, the first versions of papers (preprints) are being submitted onto preprint servers such as medRxiv and bioRxiv and made openly available within a day or two of submission. These preprints (now almost 7,000 papers on just these two sites) are being downloaded millions of times throughout the world.
However, exposing scientific content to the public before it has been peer-reviewed by experts increases the risk it will be misunderstood. Researchers need to engage with the public to improve understanding of how scientific knowledge evolves and to provide ways to question scientific information constructively.
Traditional journals have also changed their practices. Many have made research relating to the pandemic immediately available, although some have specified the content will be locked back up once the pandemic is over. For example, a website of freely available COVID-19 research set up by major publisher Elsevier states: “These permissions are granted for free by Elsevier for as long as the Elsevier COVID-19 resource center remains active.”
Publication at journals has also sped up, though it cannot compare with the phenomenal speed of preprint servers. Interestingly, it seems posting a preprint speeds up the peer-review process when the paper is ultimately submitted to a journal.
Open data
What else has changed in the pandemic? What has become clear is the power of aggregation of research. A notable initiative is the COVID-19 Open Research Dataset (CORD-19), a huge, freely available public dataset of research (now more than 130,000 articles) whose development was led by the US White House Office of Science and Technology Policy.
Researchers can not only read this research but also reuse it, which is essential to make the most of the research. The reuse is made possible by two specific technologies: permanent unique identifiers to keep track of research papers, and machine-readable conditions (licenses) on the research papers, which specify how that research can be used and reused.
These are Creative Commons licenses like those that cover projects such as Wikipedia and The Conversation, and they are vital for maximizing reuse. Often the reading and reuse is done now at least in a first scan by machines, and research that is not marked as being available for use and reuse may not even be seen, let alone used.
What has also become important is the need to provide access to data behind the research papers. In a fast-moving field of research not every paper receives detailed scrutiny (especially of underlying data) before publication—but making the data available ensures claims can be validated.
If the data can’t be validated, the research should be treated with extreme caution—as happened to a swiftly retracted paper about the effects of hydroxychloroquine published by The Lancet in May.
Overnight changes, decades in the making
While opening up research literature during the pandemic may seem to have happened virtually overnight, these changes have been decades in the making. There were systems and processes in place developed over many years that could be activated when the need arose.
The international licenses were developed by the Creative Commons project, which began in 2001. Advocates have been challenging the dominance of commercial subscription models since the early 2000s, and open access journals and other publishing routes have been growing globally since then.
Even preprints are not new. Although more recently platforms for preprints have been growing across many disciplines, their origin is in physics back in 1991.
Lessons from the pandemic
So where does publishing go after the pandemic? As in many areas of our lives, there are some positives to take forward from what became a necessity in the pandemic.
The problem with publishing during the 2003 SARS emergency wasn’t the fault of the journals—the system was not in place then for mass, rapid open publishing. As an editor at The Lancet at the time, I vividly remember we simply could not publish or even meaningfully process every we received.
But now, almost 20 years later, the tools are in place and this pandemic has made a compelling case for open publishing. Though there are initiatives ongoing across the globe, there is still a lack of coordinated, long term, high-level commitment and investment, especially by governments, to support key open policies and infrastructure.
We are not out of this pandemic yet, and we know that there are even bigger challenges in the form of climate change around the corner. Making it the default that research is open so it can be built on is a crucial step to ensure we can address these problems collaboratively.

How to safely resume exercise in the summer heat amid a global pandemic

July 28, 2020

The summer heat is always a challenge, but this year the coronavirus pandemic has added a whole new wrinkle.
In some cases, athletes—ones of all ages and abilities—are returning to vigorous activities following long stretches of inactivity stemming from the quarantine.
UVA Today turned to Arthur Weltman and Jason Allen, kinesiology professors in the University of Virginia’s Curry School of Education and Human Development, for some advice on how to safely resume exercise. They emailed us their thoughts.
Q. Does the fact that a lot of people are now returning to outdoor exercise routines during the hottest months of the year compound the risk of something bad happening?
Allen: Absolutely. “Exercise outside of the home” was designated as an essential activity in most areas during these “shelter in place” orders. However, they didn’t specifically state, “During the hottest months of the year!”
Exercise in the produces additional physiological challenges to the body. If an individual is unaccustomed to exercising and/or unaccustomed to the heat, this can increase the risk of an adverse event.
Q. What are some symptoms of heat exhaustion?
Weltman: They include: muscle cramping; fatigue; headache; nausea or vomiting; dizziness or fainting. Heat exhaustion can progress to heat stroke, whose symptoms include: a core temperature above 103 degrees; red, hot, dry skin (no sweating); rapid, strong pulse; dizziness; nausea; confusion; and loss of consciousness. It is critical to cool the body by whatever means possible if heat exhaustion or heat stroke occur. If left untreated, you essentially turn your body into an oven and allow your organs to “cook.” The most common cause of exertional heat-related death is organ failure.
Q. For people just starting to resume vigorous exercise routines that they had taken a break from during the pandemic, are there any kinds of preventive measures they can take?
Allen: In practical terms, we use the American College of Sports Medicine Guidelines to advise adults based on: A, if they are already participating in regular exercise (30 minutes for at least three days per week for the last three months); B, if they have known cardiovascular and metabolic or ; and C, if they exhibit any signs and symptoms suggestive of cardiovascular and metabolic or renal disease
The recommendation for people with no known disease and no signs and symptoms is that medical clearance is not necessary to initiate or continue light- to moderate-intensity exercise and that they can progress gradually to more vigorous activities.
Those with known disease, but without any signs and symptoms who are already regular exercisers, should continue moderate intensity activities, but get medical clearance prior to engaging in vigorous level activity (above 75% heart rate max). These people who are not regular exercisers currently are recommended to get medical clearance prior to engaging in moderate-level activity.
For anyone with signs or symptoms, regardless of disease status, they should stop exercising (or don’t start) until they undergo a medical evaluation.
Q. What are some specific guidelines that athletes and sport teams can put in place to lower the risk of heat-related illness during exercise?
Weltman:
  1. Ten to 14 days of gradually increasing duration and intensity of exercise in the heat to allow for acclimatization.
  2. Monitor hydration status daily to minimize the risk of dehydration.
  3. Consume about eight ounces of a rapidly digestible fluid (e.g. water, Gatorade) every 15 to 20 minutes during exercise in the heat and restore fluid after exercise in the heat.
  4. Modify exercise based on : cancel exercise on days when environmental conditions are dangerous; increase rest/fluid breaks when exercising in the heat; schedule workouts to an earlier or later (i.e. cooler) time of day; allow for removal of unnecessary equipment or clothing to facilitate evaporation of sweat.
Q. Are there any precautions that parents should take with their kids who are returning to sports, either this summer or in the fall?
Weltman: These common sense tips are from the CDC: Keep kids at home if they are sick or symptomatic; don’t share equipment if it can be avoided; try and keep 6 feet between players whenever possible; Coaches, parents and other spectators should wear a face covering, and if possible, players should wear face coverings as well. Players should clean their hands frequently.
Be aware of the risk. Lowest risk—individual skill-building drills and/or at home and/or with immediate family; increasing risk—team-based practice; more risk—within-team competition; even more risk—full competition between teams from the same local area; highest risk—full competition between teams from different geographic areas.
While some feel that children are less likely to become infected and/or transmit COVID-19, and will be asymptomatic or have mild symptoms if they become infected, a recent study suggested the following: children under the age of 10 have relatively low risk of contracting and transmitting COVID-19 (although the risk was not zero), while children between the ages of 10 and 18 have a similar risk as adults of contracting and transmitting COVID-19. While for the most part these older children may be asymptomatic or only exhibit mild symptoms, if they contract the virus during practice or athletic competition there is still a risk of them coming home and transmitting the virus to vulnerable members of their households. Unlike professional and some college sports, where frequent testing and a “bubble” are in place, these precautions are not available for or youth sports, and many localities are in the process of making decisions about how and when to allow children to return to organized sport.
Q. So much of the talk about athletes returning to sports has centered on coronavirus protective measures (and for good reason). But do you think an overlooked aspect of everything has been that athletes may have a higher risk of injury—say a torn knee ligament or a ruptured Achilles’ tendon—due to long layoffs?
Weltman: We have good evidence that transition periods are associated with an increased risk of catastrophic sport injuries. Examples of transition periods include, and are not limited to, the following: One, athletes new to the program (e.g. high school athletes transitioning to an intercollegiate program and the associated differences in practice duration and intensity); two, athletes returning after an injury or illness; and three, resumption of training after an academic break (e.g. winter, spring, summer breaks).
Some of the factors that place athletes at increased risk during these transition periods may be exacerbated as a result of suspension of organized team activities and social distancing due to COVID-19. Many institutions and organizations are making plans to return to organized sports, affecting more than 10 million high school and college athletes. As athletes re-engage in their sport during this unprecedented pandemic, health care providers, administrators and coaches must develop a comprehensive plan to reduce risk while reintroducing sport.

Immunoprotein impairs coronavirus

A protein produced by the human immune system can strongly inhibit corona viruses, including SARS-Cov-2, the pathogen causing COVID-19. An international team from Germany, Switzerland and the U.S. successfully showed that the LY6E-Protein prevents coronaviruses from causing an infection. “This finding might lead to the development of new therapeutic approaches against coronaviruses,” says Professor Stephanie Pfänder from the Department for Molecular and Medical Virology at Ruhr-Universität Bochum (RUB), lead author of the study published by the team in the journal Nature Microbiology on 23 July 2020.
Strengthening influenza viruses, impairing corona viruses
The LY6E protein plays a role in various diseases: US researchers Professor John Schoggins and Professor Charles Rice discovered that the protein enhances the infectivity of . In contrast, coronaviruses are inhibited by LY6E.
Funded by a Marie Curie Individual Fellowship of the European Union, Stephanie Pfänder, who was then working at the Institute of Virology and Immunology in Switzerland, visited Charles Rice’s lab at Rockefeller University in New York in 2017, in order to identify genes that prevent coronavirus infections. “This led to the discovery that LY6E has the opposite effect on coronaviruses compared to influenza viruses,” explains the researcher. Further investigations showed that the protein exerted this inhibitory effect on all analyzed coronaviruses, including the pathogens causing SARS and Mers as well as SARS-Cov-2 which causes COVID-19.
Viruses unable to fuse
Tests with different cell cultures showed that LY6E affects the ability of the to fuse with the host . “If the virus is unable to fuse with these cells, it can’t cause infection,” explains corresponding author Professor Volker Thiel from the University of Bern.
The validation in an succeeded thanks to a collaboration with the laboratory of John Schoggins at the Southwestern Medical Center of the University of Texas. The experiments conducted there led to the discovery that the mouse variant of the protein called Ly6e is crucial for the protection of immune cells against infections. In the absence of Ly6e, immune cells such as dendritic cells and B-cells become more susceptible to infection and their numbers decrease dramatically. Mice lacking Ly6e in immune cells are highly susceptible to a normally non-lethal mouse coronavirus and succumb to infection.
Understanding basic concepts
The researchers point out that the mouse coronavirus used in the experiment differs significantly from the pathogen causing the current COVID-19 outbreak—for example, it causes hepatisis rather than respiratory disease. Nevertheless, it is widely accepted as a model for understanding the basic concepts of coronavirus replication and immune responses in a living animal.
“Our study provides new insights into how important these antiviral genes are for the control of viral and for an adequate immune response against the virus,” say the authors. “Since LY6E is a naturally occurring human protein, we hope that this knowledge will aid the development of therapies that may one day be used to treat coronavirus infections.” A therapeutic approach that mimics the mechanism of action of LY6E may provide a first line of defense against novel infections.

Explore further

More information: Stephanie Pfaender et al. LY6E impairs coronavirus fusion and confers immune control of viral disease, Nature Microbiology (2020). DOI: 10.1038/s41564-020-0769-y

A Better Tau Blood Test for Diagnosing Alzheimer’s?

Researchers are making headway in developing a blood test for the presence of tau, one of the hallmarks of Alzheimer’s Disease (AD).
In one new development, experts at the University of California, San Francisco (UCSF) compared phosphorylated-tau181 (P-tau181) to a related form of tau called P-tau217 to determine which can best identify individuals with AD.
Results showed that the two biomarkers were similar overall, but P-tau 217 had a slight edge in terms of accuracy. Importantly, both tau isoforms distinguished frontotemporal lobar degeneration (FTLD).
“These new blood tests for P-tau are going to be really exciting because they will improve our ability to simply and inexpensively assess whether someone is at high risk for having Alzheimer’s Disease,” study author Adam L. Boxer, MD, PhD, professor in UCSF’s Department of Neurology, told Medscape Medical News.
Dr Adam Boxer
With the approval of the first disease-modifying therapy for AD possibly around the corner, developing an accurate diagnostic blood test for this condition is even more urgent, added Boxer, who is also director of UCSF’s Neurosciences Clinical Research Unit and AD and FTD Clinical Trials Program.